CB Scientific Inc. (CBSC) Formally Launches Next Generation MyCardia AT Cardiac Monitor
CB Scientific Inc. (CBSC) has officially launched its next generation MyCardia AT cardiac monitor in partnership with contract manufacturer Datrix, This FDA-cleared device is designed for the company's international distribution network in SE Asia, Hong Kong, and Macau.
The MyCardia AT offers an improved patient monitoring experience with its lightweight, easy-to-wear design and flexible options to transmit event recordings via iOS or Android smartphones using the MyCardia app. The device helps physicians detect cardiac arrhythmias in patients with intermittent symptoms during a 30-day monitoring period, addressing a critical health concern as ischemic heart disease deaths have increased from 2.7 million to 9.1 million since 2000.
CBSC is strategically enhancing its cardiac monitoring portfolio by integrating the device with its existing AWS Cloud-based MyCardia portal and smartphone applications. Distributors in Malaysia, Singapore, Thailand, Indonesia, Hong Kong, and Macau will begin registering the device with regulatory agencies, with plans to expand to China and Canada pending regulatory approvals.
CB Scientific Inc. (CBSC) ha ufficialmente lanciato la sua nuova generazione di monitor cardiaco MyCardia AT in collaborazione con il produttore a contratto Datrix. Questo dispositivo, approvato dalla FDA, 猫 progettato per la rete di distribuzione internazionale dell'azienda nel sud-est asiatico, a Hong Kong e a Macao.
Il MyCardia AT offre un'esperienza di monitoraggio del paziente migliorata grazie al suo design leggero e facile da indossare, con opzioni flessibili per trasmettere le registrazioni degli eventi tramite smartphone iOS o Android utilizzando l'app MyCardia. Il dispositivo aiuta i medici a rilevare le aritmie cardiache nei pazienti con sintomi intermittenti durante un periodo di monitoraggio di 30 giorni, affrontando una preoccupazione sanitaria critica poich茅 i decessi per malattia ischemica del cuore sono aumentati da 2,7 milioni a 9,1 milioni dal 2000.
CBSC sta migliorando strategicamente il suo portafoglio di monitoraggio cardiaco integrando il dispositivo con il suo portale MyCardia basato su AWS Cloud e le applicazioni per smartphone esistenti. I distributori in Malesia, Singapore, Thailandia, Indonesia, Hong Kong e Macao inizieranno a registrare il dispositivo presso le agenzie regolatorie, con piani di espansione in Cina e Canada in attesa di approvazioni normative.
CB Scientific Inc. (CBSC) ha lanzado oficialmente su pr贸xima generaci贸n de monitor card铆aco MyCardia AT en asociaci贸n con el fabricante por contrato Datrix. Este dispositivo, aprobado por la FDA, est谩 dise帽ado para la red de distribuci贸n internacional de la empresa en el sudeste asi谩tico, Hong Kong y Macao.
El MyCardia AT ofrece una experiencia mejorada de monitoreo del paciente con su dise帽o ligero y f谩cil de usar, as铆 como opciones flexibles para transmitir grabaciones de eventos a trav茅s de smartphones iOS o Android utilizando la aplicaci贸n MyCardia. El dispositivo ayuda a los m茅dicos a detectar arritmias card铆acas en pacientes con s铆ntomas intermitentes durante un per铆odo de monitoreo de 30 d铆as, abordando una preocupaci贸n de salud cr铆tica, ya que las muertes por enfermedad card铆aca isqu茅mica han aumentado de 2.7 millones a 9.1 millones desde el 2000.
CBSC est谩 mejorando estrat茅gicamente su cartera de monitoreo card铆aco al integrar el dispositivo con su portal MyCardia basado en la nube de AWS y las aplicaciones para smartphones existentes. Los distribuidores en Malasia, Singapur, Tailandia, Indonesia, Hong Kong y Macao comenzar谩n a registrar el dispositivo ante las agencias regulatorias, con planes de expansi贸n a China y Canad谩 pendientes de aprobaciones regulatorias.
CB Scientific Inc. (CBSC)電� 瓿勳暯 鞝滌“鞐呾泊 Datrix鞕� 順戨牓頃橃棳 彀劯雽� MyCardia AT 鞁灔 氇媹韯�毳� 瓿奠嫕 於滌嫓頄堨姷雼堧嫟. 鞚� FDA 鞀轨澑 鞛レ箻電� 霃欕偍鞎勳嫓鞎�, 頇嶌僵 氚� 毵堨勾鞓れ潣 甑牅 鞙犿喌 雱ろ姼鞗岉伂毳� 鞙勴暣 靹り硠霅橃棃鞀惦媹雼�.
MyCardia AT電� 臧�氤嶊碃 彀╈毄頃橁赴 靿毚 霐旍瀽鞚戈臣 iOS 霕愲姅 Android 鞀る韸疙彴鞚� 韱淀暣 MyCardia 鞎膘潉 靷毄頃橃棳 鞚措菠韸� 旮半鞚� 鞝勳啞頃� 靾� 鞛堧姅 鞙犾棸頃� 鞓奠厴鞙茧 頇橃瀽 氇媹韯半 瓴巾棙鞚� 臧滌劆頃╇媹雼�. 鞚� 鞛レ箻電� 鞚橃偓臧� 30鞚� 氇媹韯半 旮瓣皠 霃欖晥 臧勴棎鞝侅澑 歃濎儊鞚� 氤挫澊電� 頇橃瀽鞚� 鞁灔 攵�鞝曤Д鞚� 臧愳頃橂姅 雿� 霃勳泙鞚� 欤茧┌, 2000雲� 鞚错泟 項堩槇靹� 鞁灔氤戩溂搿� 鞚疙暅 靷鞛愱皜 270毵� 氇呾棎靹� 910毵� 氇呾溂搿� 歃濌皜頃� 欷戩殧頃� 瓯搓皶 氍胳牅毳� 雼る９雼堧嫟.
CBSC電� AWS 韥措澕鞖半摐 旮半皹 MyCardia 韽劯 氚� 旮办〈 鞀る韸疙彴 鞎犿攲毽紑鞚挫厴瓿� 鞛レ箻毳� 韱淀暕頃橃棳 鞁灔 氇媹韯半 韽姼韽措Μ鞓るゼ 鞝勲灥鞝侅溂搿� 臧曧檾頃橁碃 鞛堨姷雼堧嫟. 毵愲爤鞚挫嫓鞎�, 鞁标皜韽ゴ, 韮滉淡, 鞚鸽弰雱れ嫓鞎�, 頇嶌僵 氚� 毵堨勾鞓れ潣 鞙犿喌鞐呾泊霌れ潃 攴滌牅 旮瓣磤鞐� 鞛レ箻毳� 霌彪頃橁赴 鞁滌瀾頃� 瓴冹澊氅�, 欷戧淡 氚� 旌愲倶雼る鞚� 頇曥灔 瓿勴殟鞚� 攴滌牅 鞀轨澑鞚� 旮半嫟毽碃 鞛堨姷雼堧嫟.
CB Scientific Inc. (CBSC) a officiellement lanc茅 sa prochaine g茅n茅ration de moniteur cardiaque MyCardia AT en partenariat avec le fabricant sous contrat Datrix. Cet appareil, approuv茅 par la FDA, est con莽u pour le r茅seau de distribution international de l'entreprise en Asie du Sud-Est, 脿 Hong Kong et 脿 Macao.
Le MyCardia AT offre une exp茅rience de surveillance des patients am茅lior茅e gr芒ce 脿 son design l茅ger et facile 脿 porter, ainsi qu'脿 des options flexibles pour transmettre les enregistrements d'茅v茅nements via des smartphones iOS ou Android en utilisant l'application MyCardia. L'appareil aide les m茅decins 脿 d茅tecter les arythmies cardiaques chez les patients pr茅sentant des sympt么mes intermittents pendant une p茅riode de surveillance de 30 jours, abordant un probl猫me de sant茅 critique, car les d茅c猫s dus 脿 des maladies cardiaques isch茅miques ont augment茅 de 2,7 millions 脿 9,1 millions depuis 2000.
CBSC renforce strat茅giquement son portefeuille de surveillance cardiaque en int茅grant l'appareil 脿 son portail MyCardia bas茅 sur le cloud AWS et 脿 ses applications pour smartphones existantes. Les distributeurs en Malaisie, 脿 Singapour, en Tha茂lande, en Indon茅sie, 脿 Hong Kong et 脿 Macao commenceront 脿 enregistrer l'appareil aupr猫s des agences r茅glementaires, avec des plans d'expansion vers la Chine et le Canada en attente d'approbations r茅glementaires.
CB Scientific Inc. (CBSC) hat offiziell die n盲chste Generation des MyCardia AT Herzmonitors in Partnerschaft mit dem Auftragshersteller Datrix auf den Markt gebracht. Dieses von der FDA zugelassene Ger盲t ist f眉r das internationale Vertriebsnetz des Unternehmens in S眉dostasien, Hongkong und Macao konzipiert.
Der MyCardia AT bietet ein verbessertes Patientenmonitoring-Erlebnis mit seinem leichten, tragbaren Design und flexiblen Optionen zur 脺bertragung von Ereignisaufzeichnungen 眉ber iOS- oder Android-Smartphones mit der MyCardia-App. Das Ger盲t hilft 脛rzten, Herzrhythmusst枚rungen bei Patienten mit intermittierenden Symptomen w盲hrend eines 30-t盲gigen 脺berwachungszeitraums zu erkennen und adressiert ein kritisches Gesundheitsproblem, da die Todesf盲lle durch isch盲mische Herzkrankheit seit 2000 von 2,7 Millionen auf 9,1 Millionen gestiegen sind.
CBSC verbessert strategisch sein Portfolio f眉r Herzmonitoring, indem das Ger盲t in das bestehende AWS-Cloud-basierte MyCardia-Portal und die Smartphone-Anwendungen integriert wird. Distributoren in Malaysia, Singapur, Thailand, Indonesien, Hongkong und Macao werden beginnen, das Ger盲t bei den Regulierungsbeh枚rden zu registrieren, mit Pl盲nen zur Expansion nach China und Kanada, die von regulatorischen Genehmigungen abh盲ngen.
- FDA-cleared MyCardia AT cardiac monitor launched for international markets
- Device integrates with existing AWS Cloud-based MyCardia portal and smartphone apps
- Established distribution network in SE Asia, Hong Kong, and Macau
- Expansion plans for China and Canada markets in progress
- Addresses growing cardiac disease market (ischemic heart disease deaths increased from 2.7M to 9.1M since 2000)
- Pending regulatory approvals required before sales can begin in target markets
- Additional regulatory hurdles with China's NMPA still ahead
- No immediate revenue impact until regulatory approvals are secured
LAS VEGAS, NV / / February 25, 2025 / CB Scientific, Inc. ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company, in partnership with its contract manufacturer Datrix, LLC, is launching its next generation cardiac event monitor targeted for use with our international distribution network in SE Asia, Hong Kong, and Macau. The newly branded MyCardia AT device is FDA-cleared and is designed to provide an improved patient remote cardiac monitoring experience with its lightweight, easy-to-wear design, including flexible and convenient options to transmit event recordings over an iOS or Android smartphone and utilizing our MyCardia Apple, Google or WeChat app.
The MyCardia AT cardiac event monitor helps physicians detect, identify, and diagnose potential cardiac arrhythmias in patients with intermittent transient symptoms closer to the time that they occur up to a 30-day monitoring period. Early detection and treatment of cardiac rhythm disorders helps to significantly reduce the burden of cardiac disease which can damage the heart and may even lead to an increased risk of stroke and death. According to the World Health Organization, since 2000 the largest increase in deaths is from ischemic heart disease which multiplied from 2.7 million to 9.1 million, and in 2021 accounted for
The Company is strategically enhancing its remote cardiac monitoring portfolio with the launch of the MyCardia AT device. This initiative aims to leverage the strength of our established brand name to drive recognition, streamline our product ecosystem, and reinforce our market presence. The MyCardia AT marketing strategy involves seamlessly integrating with our existing AWS Cloud-based MyCardia portal and the widely adopted MyCardia iOS and Android smartphone applications, with the goal of ensuring a cohesive and optimized user experience on a global scale.
Our established distributors in Malaysia, Singapore, Thailand, Indonesia, Hong Kong, and Macau will now begin registering the MyCardia AT device with their respective regulatory agencies for import approval. Upon completion, the MyCardia AT device will begin shipping at that time and be widely available throughout these respective markets going forward. Additionally next step regulatory submission work will immediately resume for the MyCardia AT towards the approval of our representative Chinese manufacturing partner Shenzhen Pump. The Company will also continue working directly with representatives from the National Medical Products Administration (NMPA) in China towards the completion of clearance to market approval for our device into that market. Regulatory submission will also begin with our Canadian distributor Your Heart Protector Corp. towards clearance to market acceptance throughout Canada.
As additional new developments occur, plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
, through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: [email protected]
Investor Inquiries: [email protected]
Follow CBSC: , , , , , and
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View the original on ACCESS Newswire
FAQ
What is the new product launched by CB Scientific Inc. (CBSC)?
Which markets will CBSC's MyCardia AT cardiac monitor be available in?
How does the MyCardia AT cardiac monitor work with smartphones?
What is the monitoring period for CBSC's MyCardia AT cardiac device?
What regulatory approvals does CBSC need for the MyCardia AT device?
